A biotech startup from France, Osivax announced today that it has secured €8 million of financing through a Series A financing round to fund further progress in the clinical development of its lead flu vaccine candidate and to support strategic corporate growth. Osivax was founded in 2017 to translate its innovative oligoDOM technology platform into a vaccine pipeline. The most advanced program aims at inducing a paradigm shift in the prevention of seasonal and pandemic influenza.
The financing was led by Noshaq, previously known as Meusinvest, a Belgian investment firm, and joined by Anaxago, an innovative investment platform that enables individuals to participate in fundraising for early-stage companies through a holding company. Osivax has secured a total of €11 million to-date, including its seed financing from Pradeyrol Développement and other family offices as well as recent non-dilutive funding from BPI France and Wallonia region (DGO6).